Integra LifeSciences Holdings Corporation: FY2019 Form 10-K Summary
Business context and reporting period
Integra is a global medical technology company headquartered in Princeton, New Jersey. It manufactures and sells products through two reportable segments: Codman Specialty Surgical and Orthopedics and Tissue Technologies. Products address neurosurgery, surgical instrumentation, regenerative technology, wound care, extremity orthopedics, and tissue repair.
The filing covers the fiscal year ended December 31, 2019, with comparative information for 2018 and 2017. The fourth quarter is included in the annual results; fourth-quarter 2019 revenue was $395.1 million and net income was $15.3 million.
Revenue, profit, cash flow, margins, debt and liquidity
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $1,517.6 million | $1,472.4 million | Up 3.1% |
| Gross margin | 62.8% | 61.2% | Up 160 basis points |
| Operating income | $93.8 million | $111.0 million | Down 15.5% |
| Net income | $50.2 million | $60.8 million | Down 17.4% |
| Diluted earnings per share | $0.58 | $0.72 | Down $0.14 |
| Operating cash flow | $231.4 million | $199.7 million | Up $31.8 million |
- Codman Specialty Surgical revenue was $996.2 million, up 3.3%, driven primarily by dural repair, CUSA capital equipment and disposables, and programmable valves.
- Orthopedics and Tissue Technologies revenue was $521.4 million, up 2.5%. Core PriMatrix and SurgiMend tissue products grew at a mid-teens rate, while extremity orthopedic sales were flat.
- Domestic revenue was $1,077.4 million, or 71.0% of total revenue. International revenue was $440.2 million.
- Special charges totaled $163.5 million, including $124.7 million of acquisition and integration-related charges, $17.6 million of structural optimization charges, $9.2 million of discontinued product charges, $6.2 million related to EU medical device regulation, and $5.8 million of impairment charges.
- In-process research and development expense was $64.9 million, primarily related to the Rebound Therapeutics transaction, and materially reduced operating income and net income.
- Cash and cash equivalents were $198.9 million at December 31, 2019, compared with $138.8 million at year-end 2018. Working capital increased to $526.9 million from $512.5 million.
- Capital expenditures were $69.5 million. Cash paid for the Arkis and Rebound transactions was $95.5 million, net of cash acquired.
- Total external debt was approximately $1.3 billion at year-end. Outstanding borrowings included $877.5 million under the term loan, $375.0 million under the revolving credit facility, and $104.5 million under the receivables securitization facility.
- The company was in compliance with its debt covenants at December 31, 2019. No cash dividends were paid.
Material changes versus the prior comparable period
- Revenue growth was modest compared with 2018, when results benefited substantially from the full-year contribution of the 2017 Codman Neurosurgery and Derma Sciences acquisitions.
- Gross margin improved to 62.8% from 61.2%, mainly because of lower Codman acquisition and integration costs.
- Operating income and net income declined despite higher revenue because of the $64.9 million Rebound in-process research and development charge, higher acquisition-related costs, EU medical device regulation costs, impairment charges, and other special items.
- Interest expense declined to $54.0 million from $64.7 million, reflecting lower average debt balances and a lower weighted-average interest rate of 3.2% versus 3.9%.
- Operating cash flow increased, although inventory investment reduced cash generation as the company supported new product launches and manufacturing changes related to the Codman integration.
- Integra acquired Arkis Biosciences for $30.9 million plus contingent consideration of up to $25.5 million, and acquired Rebound Therapeutics for an upfront payment of $67.1 million plus potential development milestones of up to $35.0 million.
- The company completed the integration of the Codman Neurosurgery acquisition, closing 45 transition service agreements covering 90 countries, and launched ten products during 2019.
Guidance, outlook, management commentary, risks and unusual items
- Management’s strategy emphasizes execution, scale, innovation, customer experience, strategic acquisitions, portfolio optimization, commercial-channel expansion, and clinical evidence development.
- The company estimated a 2020 worldwide effective tax rate of approximately 20.0%. It also expected annual amortization expense of approximately $74.6 million in 2020, excluding future amortization associated with acquired in-process research and development.
- On February 3, 2020, Integra amended and extended its senior credit agreement to February 3, 2025. The facility provides approximately $2.2 billion of aggregate capacity, including an $877.5 million term loan and a $1.3 billion revolving facility.
- On February 4, 2020, the company issued $575.0 million of 0.5% convertible notes due 2025. It planned to use $100.0 million of proceeds for share repurchases and the remainder for general corporate purposes, including potential debt repayment. On February 10, 2020, it repaid $315.0 million of revolving debt.
- The company faces significant regulatory exposure. A 2015 FDA Untitled Letter remains outstanding concerning certain morselized amniotic membrane products. Revenue from those products was less than 1.0% of consolidated revenue in 2019, but enforcement action could affect sales.
- A March 2019 FDA Warning Letter concerning quality-system issues at the TEI Boston facility remained under remediation. The letter did not restrict manufacturing or shipments or require a product recall, but products manufactured there represented approximately 4.2% of 2019 consolidated revenue.
- Approximately 37.0% of 2019 revenue came from products containing bovine-derived material, creating exposure to animal-source regulation, BSE-related concerns, and supply restrictions.
- Key risks include acquisition integration, leverage and variable-rate debt, LIBOR transition, reimbursement and pricing pressure, medical-device regulation, product liability, intellectual property, cybersecurity, foreign exchange, sole-source suppliers, manufacturing disruptions, and potential goodwill or intangible-asset impairments.
- The company recorded a $5.8 million impairment charge related to a customer-relationship intangible asset after an FDA action affecting a contract-manufacturing customer. It also recorded a $3.0 million gain from a legal settlement in other income.
- PricewaterhouseCoopers issued an unqualified opinion on the financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2019.
Most important facts an investor should verify
- Whether the Rebound and Arkis acquisitions produce the expected commercial growth and whether additional milestone payments become payable.
- Progress and final resolution of the FDA Warning Letter concerning the TEI Boston facility and the ongoing regulatory status of BioD morselized amniotic products.
- Organic revenue growth after separating acquisition effects, foreign-exchange impacts, discontinued products, and divestitures.
- Whether the improved gross margin is sustainable after special charges, integration costs, and product-mix changes normalize.
- Debt reduction, covenant headroom, refinancing requirements, and exposure to LIBOR replacement and variable interest rates.
- The effect of the February 2020 convertible notes, related share repurchases, note hedges, and warrants on leverage and potential dilution.
- Assumptions supporting the $954.3 million goodwill balance and $163.1 million indefinite-lived Codman trade name, including projected growth and discount rates.
- Inventory growth, product obsolescence risk, and the company’s ability to convert operating cash flow into sustained free cash flow.